Eli Lilly announced on Friday that it has submitted an application for U.S. approval of its weight loss medication Zepbound to treat obstructive sleep apnea, with a decision expected by the end of the year. If approved by the FDA, the company aims to launch Zepbound for this condition in early 2025.
In addition, Eli Lilly shared new data from clinical trials demonstrating that Zepbound effectively resolved obstructive sleep apnea in nearly half of the patients. This promising data was presented at the American Diabetes Association’s 84th Scientific Sessions in Orlando, Florida.
Patrik Jonsson, president of Eli Lilly diabetes and obesity, expressed enthusiasm about the results, stating that they exceeded expectations. The company is eager to provide a solution for individuals suffering from this common sleep disorder.
2024-06-21 15:29:35
Article from www.cnbc.com